Drug Profile
ODM 208
Alternative Names: MK-5684; ODM-208Latest Information Update: 12 Apr 2024
Price :
$50
*
At a glance
- Originator Orion
- Developer Merck Sharp & Dohme; Orion
- Class Antineoplastics; Small molecules
- Mechanism of Action Cholesterol side chain cleavage enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Prostate cancer
Most Recent Events
- 09 Apr 2024 Merck Sharp & Dohme plans a phase I/II trial for Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater, Monotherapy, Combination therapy) in May 2024 (PO) (NCT06353386)
- 30 Jan 2024 Phase-I clinical trials in Prostate cancer (Metastatic disease, Combination therapy, Second-line therapy or greater, Hormone refractory) in China (PO) (NCT06136598)
- 26 Jan 2024 Efficacy and adverse events data from a phase I/II CYPIDES trial in Prostate cancer released by Orion